Ventripoint Strengthens Board with Appointment of MedTech Executive and Commercialization Leader Dr. Philip Toleikis
TheNewswire
Published: Jul 30, 2026, 05:55 AM GMT+9
Sentiment Analysis
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV: VPT; OTC: VPTDF), a leader in AI-powered cardiac imaging, today announced the appointment of Dr. Philip M. Toleikis to its Board of Directors, adding extensive public company leadership, capital markets expertise, and medical technology commercialization experience as the Company accelerates the global expansion of its VMS+ cardiac imaging platform.
Dr. Toleikis is a seasoned life sciences executive with a proven track record of building innovative healthcare companies, securing capital, developing strategic partnerships, and creating shareholder value. His appointment further strengthens Ventripoint's governance as the Company advances commercial execution and positions itself for growth.
"Philip brings an exceptional combination of scientific innovation, operational leadership and public market experience," said Hugh MacNaught President and CEO of Ventripoint Diagnostics. "He has successfully led a disruptive medical technology company through every stage of growth - from technology development and intellectual property creation to clinical advancement, financing, strategic partnerships and exchange graduation. His experience will be instrumental as Ventripoint continues to expand adoption of VMS+, pursue strategic collaborations, and build long-term shareholder value."
"I have followed Ventripoint's progress with great interest and believe the Company is well positioned to transform how ventricular function is quantified in routine clinical practice," said Dr. Toleikis. "The ability to provide MRI-equivalent volumetric assessment using standard echocardiography addresses a significant clinical and economic need for healthcare systems worldwide. I look forward to working with the Board and management team to help accelerate commercialization, strengthen strategic partnerships, and maximize value for patients, clinicians and shareholders."
Dr. Toleikis most recently served as President, Chief Executive Officer, Director and Chief Technology Officer of Sernova Corp., where he led the company through a period of transformational growth. During his 13-year tenure, he secured more than $100 million through equity financings, strategic investments, convertible debt and non-dilutive government funding while expanding relationships with retail, institutional and banking partners. Under his leadership, Sernova graduated from the TSX Venture Exchange to the Toronto Stock Exchange and increased its market capitalization from approximately $3 million to more than $350 million.
Beyond capital formation, Dr. Toleikis established global strategic collaborations with leading academic institutions and pharmaceutical companies, negotiated worldwide licensing agreements, expanded an international intellectual property portfolio, and built multidisciplinary teams spanning research and development, clinical operations, regulatory affairs, finance, investor relations and business development.
Earlier in his career, Dr. Toleikis served as Vice President of Research & Development at Angiotech Pharmaceuticals, where he contributed to the development of one of the first commercially successful drug-eluting coronary stents in collaboration with Boston Scientific. He also conducted research in a cardiac ultrasound laboratory focused on three-dimensional assessment of left ventricular function—experience that provides a unique understanding of the clinical challenges Ventripoint's VMS+ platform is designed to address.
Dr. Toleikis has authored more than 100 issued patents and patent applications and numerous peer-reviewed scientific publications cov...
Source: TheNewswire
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.